| 词条 | Obiltoxaximab |
| 释义 |
| type = mab | image = | alt = | mab_type = mab | source = xi/o | target = Bacillus anthracis anthrax | tradename = Anthim | Drugs.com = {{drugs.com|cons|anthim}} | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 1351337-07-9 | ATC_prefix = J06 | ATC_suffix = BB22 | PubChem = | DrugBank = DB05336 | ChemSpiderID = none | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D10776 | C=6444 | H=9994 | N=1734 | O=2022 | S=44 | molecular_weight = 145.5 kg/mol | UNII = 29Z5DNL48C | synonyms = ETI-204 }}Obiltoxaximab (ETI-204, trade name Anthim) is a monoclonal antibody designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).[1] This drug was developed by Elusys Therapeutics, Inc. References1. ^Statement On A Nonproprietary Name Adopted By The USAN Council - Obiltoxaximab, American Medical Association. {{monoclonals for infectious disease and toxins}}{{monoclonal-antibody-stub}}{{antiinfective-drug-stub}} 2 : Monoclonal antibodies|Experimental drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。